Inactive Instrument

Momenta Pharmaceuticals, Inc.

MNTA

US60877T1007

Biotechnology & Medical Research

MOMENTA PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-K)

January 03, 2020 at 08:02 am EST

brli:measure>iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported):  December 27, 2019

Momenta Pharmaceuticals, Inc.

Latest news about Momenta Pharmaceuticals, Inc.

Momenta Pharmaceuticals, Inc. Announces Executive Changes	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P TMI Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P 1000	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P Global BMI Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P Biotechnology Select Industry Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P 600 Health Care	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P Composite 1500	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGS:MNTA) dropped from S&P 600	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell Small Cap Comp Value Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Value Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Value Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 3000 Value Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell Small Cap Comp Growth Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Growth Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Growth Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 3000 Growth Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell Small Cap Completeness Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 3000 Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Value-Dynamic Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Growth-Dynamic Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Value-Dynamic Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2000 Dynamic Index	20-10-01	CI
Momenta Pharmaceuticals, Inc.(NasdaqGM:MNTA) dropped from Russell 2500 Dynamic Index	20-10-01	CI

Chart Momenta Pharmaceuticals, Inc.

Duration

Period

More charts

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+2.73%	108B
REGENERON PHARMACEUTICALS, INC.	+10.07%	105B
ARGENX SE	+1.57%	23.46B
BIONTECH SE	-11.99%	21.72B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-37.64%	17.45B
BEIGENE, LTD.	-6.87%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.95%	13.99B
SAREPTA THERAPEUTICS, INC.	+36.05%	12.53B

Bio Therapeutic Drugs